Skip to main content
Addgene

pLKO.1-TRC.mKO2
(Plasmid #85208)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 85208 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pLKO.1 - TRC cloning vector
  • Backbone manufacturer
    David Root (Addgene #10878)
  • Backbone size (bp) 7032
  • Modifications to backbone
    Puromycin N-acetyltransferase resistance was removed with BamHI and KpnI and inserted monomeric Kusabira-Orange2 for fluorescence expression.
  • Vector type
    Mammalian Expression, Lentiviral, RNAi
  • Promoter RNA polymerase III promoter for human U6 snRNA for shRNA and hPGK promoter for mKO2

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    High Copy

Cloning Information

Resource Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.

Depositor Comments

The 1.9kb stuffer can be released with AgeI and EcoRI and replaced with your shRNA sequence of choice.

Also, see Addgene's pLKO.1 protocol http://www.addgene.org/plko on how to use the pLKO.1 vector.

Plasmid grows more slowly than standard plasmids.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pLKO.1-TRC.mKO2 was a gift from Sandra Martha Gomes Dias (Addgene plasmid # 85208 ; http://n2t.net/addgene:85208 ; RRID:Addgene_85208)
  • For your References section:

    Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer. Quintero M, Adamoski D, Reis LMD, Ascencao CFR, Oliveira KRS, Goncalves KA, Dias MM, Carazzolle MF, Dias SMG. BMC Cancer. 2017 Nov 7;17(1):727. doi: 10.1186/s12885-017-3726-2. 10.1186/s12885-017-3726-2 [pii] PubMed 29115931